AGENT therapy

If initial FPG greater than or equal to 210 mg/dL (11.7 mmol/L) or, Hemoglobin A1c(HbA1c) greater than or equal to 9.0%, consider dual oral agent therapy... 

Examples of other agents include trazodone (50 to 200 mg/day), yohimbine (5.4 mg three times daily), papaverine (7.5 to 60 mg [single agent therapy] or 0.5 to 20 mg [combination therapy] intracavernosal injection), and phentolamine (1 mg [combination therapy] intracavernosal injection). 

F. Role in therapy According to Micro-medex, single-agent therapy with gem-tuzumab ozogamicin has produced remission in some patients with relapsed or refractory acute myelogenous leukemia. The selective ablation of leukemic cells with this agent is an advantage over conventional chemotherapy. 

Our group [69] studied in vivo half-life in 24 children (2-15 years) with acute lymphocytic leukemia under multiple agent therapy including E coli 1-ASP... 

Indications ACE inhibitors may be considered for single-agent therapy in patients who present with mild dyspnea on exertion and who do not show signs or symptoms of volume overload. ACE inhibitors are useful in decreasing CHF in asymptomatic patients with ejection fraction less than 35% (left ventricular dysfunction). Patients who have had a recent myocardial infarction also benefit from long-term ACE inhibitor therapy. Patients with the lowest ejection fraction show the greatest benefit. Early use of ACE... 

DISOPYRAMIDE CALCIUM CHANNEL BLOCKERS Risk of myocardial depression and asystole when disopyramide is co administered with verapamil, particularly in the presence of heart failure Disopyramide is a myocardial depressant like verapamil and can cause ventricular tachycardia, ventricular fibrillation or torsades de pointes Avoid co administering verapamil with disopyramide if possible. If single-agent therapy is ineffective, monitor PR, BP and ECG closely watch for heart failure... 

Figure 18.1 is an example of a dose-effect study with a molecular endpoint. Patients who were scheduled for resection of their brain tumor received a dose of O -benzylguanine (O -BG) intravenously 10 to 27 hours prior to surgery (1). O -BG irreversibly inactivates the DNA repair protein O -alkylguanine-DNA alkyltransferase (AGT)/ which mediates resistance to some alkylating agent therapy in brain tumors. To determine the dose of O -BG that most effectively... 

---